Localized Unresectable Thymic Carcinoma Treated with Induction Chemotherapy with Lenvatinib before Radiotherapy
Authors:
Open Access
- 1 June 2025
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64 (11) , 1724-1727
Abstract
Thymic carcinoma (TC) is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot be surgically removed. To date, there have been no reports of lenvatinib being used as induction chemotherapy prior to radiotherapy in cases of localized, unresectable thymic carcinoma. We herein report an 85-year-old Japanese woman with localized unresectable thymic carcinoma who was treated with lenvatinib as induction chemotherapy before undergoing radiotherapy. Our findings suggest that lenvatinib may be a viable option for induction chemotherapy in similar clinical scenarios.Keywords
This publication has 10 references indexed in Scilit:
- Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trialLung Cancer, 2024
- Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular CarcinomaTargeted Oncology, 2024
- Successful resection after first‐line lenvatinib therapy in an advanced thymic carcinomaThoracic Cancer, 2023
- Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trialThe Lancet Healthy Longevity, 2021
- Radiotherapy for thymic epithelial tumours: a reviewTranslational Lung Cancer Research, 2021
- Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trialThe Lancet Oncology, 2020
- Intensity Modulated Radiation Therapy Plus Etoposide/Cisplatin for Patients With Limited Advanced Unresectable Thymic Epithelial Tumors: A Prospective Phase 2 StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Outcome of nonsurgical treatment for locally advanced thymic tumorsJournal of Thoracic Disease, 2016
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.Journal of Clinical Oncology, 1997